Contribute Try STAT+ Today

The various companies that made and sold Zantac over the past 36 years are being sued for allegedly failing to disclose that the popular heartburn drug can produce traces of a chemical that is a possible carcinogen and, as a result, “thousands of people” across the U.S. have developed cancer.

In three separate lawsuits, consumers contended the companies “deliberately refused” to test Zantac, because they knew that ingesting high quantities of the chemical, which is known as NDMA, posed serious health risks. The suits contended that several animal studies “overwhelmingly” linked NDMA to cancer, and also cited epidemiological studies in humans suggesting that NDMA could cause cancer

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.